Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Daniel B. Levine is of counsel in the firm’s Shanghai office.  He advises Chinese and non-Chinese companies in complex outbound and inbound direct investment transactions.  Formerly resident in the firm’s New York office, Mr. Levine has extensive experience with both China-based and non-China-based public and private mergers and acquisitions, venture capital investments, joint ventures, leveraged buy-outs, going-private transactions, and other transactional matters.  He frequently speaks and writes on trends in Chinese outbound direct investment and strategies for approaching destination country legal and regulatory challenges, including national security reviews in the United States by the Committee on Foreign Investment in the United States (CFIUS).

  • LONGi Green Energy Technology Co. Ltd. in its acquisition of a Malaysian manufacturing facility from and commercial agreements with SunEdison.
  • Origin Technologies Corporation, LLC in connection with its $1.8 billion bid for Affymetrix, Inc.
  • A leading Chinese technology company in a minority investment in a leading global content company.
  • AstraZeneca in a strategic alliance with WuXi Apptec, including an option to acquire a biologics manufacturing facility in Wuxi City.
  • A leading multinational pharma company in an option to acquire, and a minority investment in, a China-based innovative and pharma company.
  • Cathay Pacific in the negotiation of a long-term distribution agreement with a leading GDS.
  • A specialty healthcare company in its licensing of marketing rights for OTC consumer drugs.
  • Telular Corporation in its sale to Avista Capital Partners for $253 million.
  • Illumina, Inc. in its acquisition of Verinata Health, Inc. for up to $450 million in upfront and contingent payments.
  • MidFirst Bank in its acquisition of Presidential Financial Corporation from Harbert Private Equity and the Belfer family.
  • One Equity Partners in its minority investment in Grupo Phoenix, a leading packaging company in the Americas.
  • A leading private equity fund in the formation of the largest veterinary products company in the United States and the subsequent sale of the fund’s interest therein.
  • A leading middle-market private equity fund in the initial and add-on acquisitions forming the largest integrated retail property services firm in North America.

Previous Experience

  • Bear, Stearns & Co., Inc., Vice President (Financial Analytics and Structured Transactions Group), Associate (Corporate Finance Department) (1997-2001)
  • New York Super Lawyers, Mergers & Acquisitions "Rising Star" (2013)